Xtl Biopharmaceuticals (XTLB) Enterprise Value (2009 - 2025)
Xtl Biopharmaceuticals (XTLB) posted quarterly Enterprise Value of -$76000.0 for Q4 2025, up 93.35% year-on-year from -$39306.8 in Q4 2024, and up 70.66% on a QoQ basis from -$259000.0 in Q2 2025.
Xtl Biopharmaceuticals (XTLB) Enterprise Value (2009 - 2025) Analysis & Trends
Xtl Biopharmaceuticals (XTLB) has reported Enterprise Value for 17 consecutive years, with -$76000.0 the latest figure, recorded in Q4 2025.
- Quarterly Enterprise Value rose 93.35% year-over-year to -$76000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$76000.0 (up 93.35% YoY) and the FY2025 annual result came in at -$76000.0, up 93.35% from the prior year.
- Enterprise Value grew to -$76000.0 in Q4 2025 per XTLB's latest filing, from -$259000.0 in the prior quarter.
- Over the last five years, Enterprise Value for XTLB reached as high as -$76000.0 in Q4 2025 and fell as low as -$6.3 million in Q2 2021.
- A 5-year average of -$2.7 million and a median of -$2.4 million in 2023 frame the typical range for Enterprise Value.
- Annual changes were most pronounced in 2021 — Enterprise Value tumbled 65.23% — and 2025, when it surged 93.35%.
- Year by year, Enterprise Value stood at -$6.1 million in 2021, then surged by 39.27% to -$3.7 million in 2022, then soared by 46.09% to -$2.0 million in 2023, then soared by 43.02% to -$1.1 million in 2024, then jumped by 93.35% to -$76000.0 in 2025.
- According to Business Quant data, Enterprise Value over the past three periods registered -$76000.0, -$259000.0, and -$1.1 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -1.91 Bn |
| 10 | Xtl Biopharmaceuticals | 2.58 Bn | 2.58 Bn | - | -76,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -76,000.00 |
| Jun 30, 2025 | -259,000.00 |
| Dec 31, 2024 | -1.14 Mn |
| Sep 30, 2024 | -1.72 Mn |
| Jun 30, 2024 | -1.59 Mn |
| Mar 31, 2024 | -2.34 Mn |
| Dec 31, 2023 | -2.01 Mn |
| Sep 30, 2023 | -2.21 Mn |
| Jun 30, 2023 | -2.38 Mn |
| Mar 31, 2023 | -2.88 Mn |
| Dec 31, 2022 | -3.72 Mn |
| Sep 30, 2022 | -2.23 Mn |
| Jun 30, 2022 | -5.16 Mn |
| Mar 31, 2022 | -2.79 Mn |
| Dec 31, 2021 | -6.13 Mn |
| Sep 30, 2021 | -3.01 Mn |
| Jun 30, 2021 | -6.30 Mn |
| Mar 31, 2021 | -3.39 Mn |
| Dec 31, 2020 | -6.04 Mn |
| Sep 30, 2020 | -3.75 Mn |